检索结果-南通市图书馆

Metabolic dysfunction-associated steatotic liver disease:Navigating terminological evolution,diagnostic frontiers and therapeutic horizon-an editorial exploration

引用

World Journal of Gastroenterology 2024年第18期30卷 2387-2390页

作者： Aleksandra Boldys lukasz buldak Department of Internal Medicine and Clinical Pharmacology School of Medicine in KatowiceMedical University of SilesiaKatowice 40-752Poland

Metabolic dysfunction-associated steatotic liver disease(MASLD),once known as non-alcoholic fatty liver disease(NAFLD),represents a spectrum of liver disorders characterized by lipid accumulation within *** redefinition of NAFLD in 2023 marked a significant reposition in terminology,emphasizing a broader understanding of liver steatosis and its associated *** is now recognized as a major risk factor for liver cirrhosis,hepatocellular carcinoma,and systemic complications such as cardiovascular diseases or systemic *** challenges arise,particularly in identifying MASLD in lean individuals,necessitating updated diagnostic protocols and investing in non-invasive diagnostic ***,there is an urgent need for effective treatments targeting MASLD,with emerging pharmacological options focusing on,among others,carbohydrate and lipid ***,understanding the roles of bile acid metabolism,the microbiome,and dietary interventions in MASLD pathogenesis and management holds promise for innovative therapeutic *** is a strong need to emphasize the importance of collaborative efforts in understanding,diagnosing,and managing MASLD to improve physicians’approaches and patient outcomes.

关键词： Metabolic dysfunction-associated steatotic liver disease Diagnostics Pathophysiology of metabolic dysfunction-associated steatotic liver disease Therapy of metabolic dysfunction-associated steatotic liver disease Therapeutic innovations

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

引用

World Journal of Gastroenterology 2017年第14期23卷 2613-2624页

作者： Michal Kukla Marek Waluga Michal Zorniak Agnieszka Berdowska Piotr Wosiewicz Tomasz Sawczyn Rafal J buldak Marek Ochman Katarzyna Ziora Tadeusz Krzemiński Marek Hartleb Department of Gastroenterology and Hepatology Medical University of Silesia in Katowice Department of Microbiology and Biotechnology Jan Dlugosz University Department of Physiology Medical University of Silesia in Katowice Department of Biochemistry in Zabrze Medical University of Silesia in Katowice Department of Cardiac Surgery and Transplantation Silesian Center for Heart Diseases Department of Pediatrics Medical University of Silesia in Katowice Department of Pharmacology Medical University of Silesia in Katowice

AIM To investigate serum omentin and vaspin levels in cirrhotic patients; and to assess the relationship of these levels with hemostatic parameters, metabolic abnormalities, cirrhosis severity and *** Fifty-one cirrhotic patients(17 with portal vein thrombosis) were analyzed. Serum omentin and vaspin levels were measured with commercially available direct enzyme-linked immunosorbent assays(ELISAs). To assess platelet activity, the following tests were performed using a MULTIPLATE?PLATELET FUNCTION ANALYZER:(1) an ADP-induced platelet activation test;(2) a cyclooxygenase dependent aggregation test(ASPI test);(3) a von Willebrand factor and glycoprotein Ibdependent aggregation(using ristocetin) test(RISTO test); and(4) a test for thrombin receptor-activating peptide-6 induced activation of the thrombin receptor, which is sensitive to Ⅱb/Ⅲa receptor antagonists. RESULTS Omentin, but not vaspin, serum concentrations were significantly decreased in patients with portal vein thrombosis(PVT)(P = 0.01). Prothrombin levels were significantly increased in patients with PVT(P = 0.01). The thrombin receptor activating peptide(TRAP) test results were significantly lower in the PVT group(P = 0.03). No significant differences in adipokines serum levels were found regarding the etiology or severity of liver cirrhosis assessed according to the Child-Pugh or Model of End-Stage Liver Disease(MELD) scores. There was a significant increase in the TRAP(P = 0.03), ASPI(P = 0.001) and RISTO high-test(P = 0.02) results in patients with lower MELD scores. Serum omentin and vaspin levels were significantly down-regulated in patients without insulin resistance(P = 0.03, P = 0.02, respectively). A positive relationship between omentin and vaspin levels were found both when all of the patients were analyzed(r = 0.41, P = 0.01) and among those with PVT(r = 0.94, P < 0.001).CONCLUSION Serum omentin levels are increased in patients without PVT. Cirrhosis origin and grade do not affect

关键词： Omentin Vaspin 肝硬化 Adipokine 门静脉血栓门高血压

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：